Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

Kelly was interviewing conservative journalist Batya Ungar-Sargon when she made the dubious claim about the disgraced ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

Mixed options sentiment in Moderna (MRNA), with shares down $1.15 near $25.56. Options volume running well above average with 49k contracts traded ...

Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.” ...

Delaware says COVID-19 vaccines are available at state clinics, regardless of insurance status. But only 2 clinics carried ...

Read more from STAT’s Chelsea Cirruzzo and Daniel Payne for more details on what Vance had to say and what attendees received ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...